February 21, 2020
Important Step Forward for PAs
Legislation Aims to Remove Barriers for PAs, Patients
By Jonathan Sobel, PA-C, MBA, DFAAPA, FAPACVS, president and chair of AAPA’s Board of Directors.
Recently, the U.S. House of Representatives passed H.R. 6, the Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act of 2018. The SUPPORT Act would permanently extend the waiver program that allows PAs to prescribe buprenorphine for treatment of opioid use disorder (OUD). While it still needs to pass the Senate and be signed by the President, this is a significant step forward for our patients.
I am confident that PAs are critical to the solution and will continue to have an expanded role in treating those affected by OUD. Legislation such as the SUPPORT Act is critical in making that a reality.
So, I urge you to contact your senators and ask them to support comprehensive legislation addressing the opioid epidemic that makes permanent the ability of PAs to prescribe buprenorphine for OUD. I also hope you will consider taking the free training to prescribe buprenorphine to treat OUD. Together, we can make a difference.
For more information: